CRISPR Therapeutics AG Profit Margin

The latest profit margin for CRSP is -3368.72% as of June 2026. That compares with -1281.85% in the prior-year period — down 162.8% year over year. That is below the Healthcare sector average of 13.76%. Investors often review this figure alongside CRISPR Therapeutics AG's historical trend and sector peers before judging valuation or financial health.

Over the past year, CRSP's profit margin moved from -1281.85% to -3368.72% — a 162.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in CRISPR Therapeutics AG's valuation or profitability profile.

Against Healthcare companies, CRSP currently prints -3368.72% for profit margin, while the sector average sits near 13.76%. That is roughly 24581.4% below the sector mean. Large gaps often invite a closer look at CRISPR Therapeutics AG's growth, margins, and balance sheet.

Profit Margin shows how effectively CRISPR Therapeutics AG converts resources into returns. At -3368.72%, CRSP may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1281.85% in the prior-year period — down 162.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CRSP's profit margin (-3368.72%), review year-over-year change from -1281.85%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.